tiprankstipranks
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders StocksMarket MoversTipRanks 50 IndexAI StocksLargest Companies by Market Cap
ETFs
Top ETFs by UpsideTop ETFs by Smart ScoreTop Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Research Tools
Trending StocksCompare StocksCompare ETFsTrump Dashboard
New
Daily Feeds
Daily Analyst RatingsDaily Insider Trading Tracker
Calendars
Earnings CalendarDividend CalendarEconomic CalendarIPO CalendarStock SplitsStock BuybacksMarket Holidays
Calculators
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Economic Indicators
Inflation RateUnemployment Rate
Class Actions
Stock ScreenerETF Screener
Popular
Penny Stock ScreenerTechnical Analysis Screener
Dividend CenterBest Dividend Stocks
Popular
Best High Yield Dividend StocksDividend AristocratsDividend Stock Comparison
New
Dividend CalculatorDividend Returns ComparisonDividend Calendar
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Trending News
More News >
Education
Personal FinanceHow To Use TipRanksTipRanks LabsWebinar CenterGlossaryFAQs
About Us
About TipRanksContact UsCareersReviewsMobile APP
Working with TipRanks
Enterprise SolutionsAdvertise with UsTop Online BrokersBecome an AffiliateTipRanks News Wire
Follow Us
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Market Movers
Compare stocks
Compare ETFs
Notification Center
News
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders Stocks
Compare Stocks
Compare ETFs
Trending Stocks
Daily Analyst Ratings
Daily Insiders Trades
Dividend Stocks
ETF Center
Top Gainers/losers/active ETFs
Trump Dashboard
New
Dividend Calculator
Options Profit Calculator
Dollar Cost Averaging
Compound Interest Calculator
Mortgage Calculator
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
Market Holidays
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Top Gainers
Top Losers
Most Active
Premarket
After-hours
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Real Estate
Top Online Brokers
Enterprise Solutions
Plans & Pricing
Education
How To Use TipRanks
TipRanks Labs
Webinar Center
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA
Advertisement
Advertisement

IMUX Stock Latest News

Promising Efficacy and Safety of Vidofludimus Calcium in MS Trials Reinforces Buy Rating
RatingsPromising Efficacy and Safety of Vidofludimus Calcium in MS Trials Reinforces Buy Rating
11d ago
IMUX
Immunic, Inc. Advances Multiple Sclerosis Drug Trials
PremiumCompany Announcements
Immunic, Inc. Advances Multiple Sclerosis Drug Trials
15d ago
IMUX
Immunic Advances Phase 3 Trials and Financial Health
PremiumCompany Announcements
Immunic Advances Phase 3 Trials and Financial Health
16d ago
8K
IMUX
Immunic reports Q2 EPS (20c), consensus (16c)
PremiumThe Fly
Immunic reports Q2 EPS (20c), consensus (16c)
16d ago
IMUX
Immunic announces vidofludimus calcium trial data
PremiumThe Fly
Immunic announces vidofludimus calcium trial data
3M ago
IMUX
Immunic completes enrollment for both ENSURE trials
PremiumThe FlyImmunic completes enrollment for both ENSURE trials
3M ago
IMUX
Immunic Approves Equity Plan Amendment at Annual Meeting
Premium
Company Announcements
Immunic Approves Equity Plan Amendment at Annual Meeting
3M ago
8K
IMUX
Immunic Announces $65 Million Public Offering
Premium
Company Announcements
Immunic Announces $65 Million Public Offering
3M ago
8K
IMUX
Immunic price target lowered to $10 from $17 at D. Boral Capital
PremiumThe Fly
Immunic price target lowered to $10 from $17 at D. Boral Capital
3M ago
IMUX
Immunic announces pricing of $65M public offering
PremiumThe Fly
Immunic announces pricing of $65M public offering
3M ago
IMUX
Immunic Announces Public Offering to Fund Trials
PremiumCompany Announcements
Immunic Announces Public Offering to Fund Trials
3M ago
8K
IMUX
Immunic announces offering of warrants to purchase common stock
PremiumThe Fly
Immunic announces offering of warrants to purchase common stock
3M ago
IMUX
Immunic price target lowered to $5 from $6 at B. Riley
PremiumThe FlyImmunic price target lowered to $5 from $6 at B. Riley
3M ago
IMUX
Buy Rating Affirmed for Immunic’s Vidofludimus Calcium Due to Promising Phase 2 Results and Strong MS Treatment Potential
Premium
Ratings
Buy Rating Affirmed for Immunic’s Vidofludimus Calcium Due to Promising Phase 2 Results and Strong MS Treatment Potential
3M ago
IMUX
Immunic’s Promising Clinical Data and Strategic Financial Position Justify Buy Rating
Premium
Ratings
Immunic’s Promising Clinical Data and Strategic Financial Position Justify Buy Rating
3M ago
IMUX
Positive Phase 2 Trial Results for VidoCa in PMS Bolster Buy Rating for Immunic
PremiumRatings
Positive Phase 2 Trial Results for VidoCa in PMS Bolster Buy Rating for Immunic
3M ago
IMUX
Biotech Alert: Searches spiking for these stocks today
PremiumThe Fly
Biotech Alert: Searches spiking for these stocks today
4M ago
ATOS
CYCC
Promising Phase 2 Results for Vidofludimus Calcium in Progressive Multiple Sclerosis Highlight Potential for Neuroprotection and Disease Modification
PremiumRatings
Promising Phase 2 Results for Vidofludimus Calcium in Progressive Multiple Sclerosis Highlight Potential for Neuroprotection and Disease Modification
4M ago
IMUX
Immunic price target raised to $22 from $19 at Brookline
PremiumThe Fly
Immunic price target raised to $22 from $19 at Brookline
4M ago
IMUX
Immunic’s Vidofludimus Calcium Shows Promise in Treating Progressive MS: Analyst Upgrades to Buy
PremiumRatingsImmunic’s Vidofludimus Calcium Shows Promise in Treating Progressive MS: Analyst Upgrades to Buy
4M ago
IMUX
Immunic’s vidofludimus calcium shows positive results in Phase 2 PMS trial
Premium
The Fly
Immunic’s vidofludimus calcium shows positive results in Phase 2 PMS trial
4M ago
IMUX
Immunic’s Vidofludimus Calcium: A Promising MS Treatment with Dual Mechanism and Positive Trial Results Justifying Buy Rating
Premium
Ratings
Immunic’s Vidofludimus Calcium: A Promising MS Treatment with Dual Mechanism and Positive Trial Results Justifying Buy Rating
4M ago
IMUX

Trending

Name
Price
Price Change
SPX
S&P 500
DJIA
Dow Jones
NDX
Nasdaq 100
More Trending Stocks >